Cargando…
LRRK2 and the Endolysosomal System in Parkinson’s Disease
Mutations in leucine-rich repeat kinase 2 (LRRK2) cause autosomal dominant familial Parkinson’s disease (PD), with pathogenic mutations enhancing LRRK2 kinase activity. There is a growing body of evidence indicating that LRRK2 contributes to neuronal damage and pathology both in familial and sporadi...
Autores principales: | Erb, Madalynn L., Moore, Darren J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677880/ https://www.ncbi.nlm.nih.gov/pubmed/33044192 http://dx.doi.org/10.3233/JPD-202138 |
Ejemplares similares
-
LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson’s disease
por: Rocha, Emily M., et al.
Publicado: (2019) -
The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System
por: Kuwahara, Tomoki, et al.
Publicado: (2020) -
Contribution of GTPase activity to LRRK2-associated Parkinson disease
por: Tsika, Elpida, et al.
Publicado: (2013) -
Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo
por: Kluss, Jillian H., et al.
Publicado: (2021) -
LRRK2-Related Parkinson’s Disease Due to Altered Endolysosomal Biology With Variable Lewy Body Pathology: A Hypothesis
por: Rivero-Ríos, Pilar, et al.
Publicado: (2020)